{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:56:07Z","timestamp":1789210567578,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":2730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1093\/annonc\/mdr533","type":"journal-article","created":{"date-parts":[[2011,11,6]],"date-time":"2011-11-06T00:55:47Z","timestamp":1320540947000},"page":"1549-1555","source":"Crossref","is-referenced-by-count":105,"title":["Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy"],"prefix":"10.1016","volume":"23","author":[{"given":"D.Y.","family":"Heng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"MacKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.N.","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A.","family":"Bjarnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kollmannsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"North","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Donskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr533_bb0010","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/cncr.22827","article-title":"Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy","volume":"110","author":"Choueiri","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr533_bb0015","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/cncr.24051","article-title":"A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer","volume":"115","author":"Heng","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr533_bb0020","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr533_bb0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr533_bb0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr533_bb0035","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr533_bb0040","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr533_bb0045","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr533_bb0050","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr533_bb0055","unstructured":"AMMolinaMSGinsbergRJMotzerLong-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinibMed Oncol2011 [epub ahead of print]"},{"key":"10.1093\/annonc\/mdr533_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2009.12.031","article-title":"Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy","author":"Vickers","year":"2010","journal-title":"Urology"},{"key":"10.1093\/annonc\/mdr533_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2010.11.003","article-title":"Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma","author":"Filson","year":"2011","journal-title":"Urology"},{"key":"10.1093\/annonc\/mdr533_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.juro.2009.02.119","article-title":"Sequential sorafenib and sunitinib for renal cell carcinoma","volume":"182","author":"Sablin","year":"2009","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdr533_bb0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.juro.2007.08.127","article-title":"Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy","volume":"179","author":"Tamaskar","year":"2008","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdr533_bb0080","doi-asserted-by":"crossref","unstructured":"CPortaGProcopioGCarten\u00ecSequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient casesBJU Int2011 May 23 [epub ahead of print]","DOI":"10.1111\/j.1464-410X.2011.10186.x"},{"key":"10.1093\/annonc\/mdr533_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr533_bb0090","doi-asserted-by":"crossref","first-page":"835680","DOI":"10.1155\/2010\/835680","article-title":"Molecular mechanisms of resistance to tumour anti-angiogenic strategies","volume":"2010","author":"Grepin","year":"2010","journal-title":"J Oncol"},{"key":"10.1093\/annonc\/mdr533_bb0095","article-title":"Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy","author":"Richey","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdr533_bb0100","article-title":"Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial","volume":"29","author":"Rini","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419387307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419387307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/6\/1549\/405155\/mdr533.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:29:02Z","timestamp":1624699742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419387307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0923753419387307"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr533","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}